A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe
and effective treatment for people with primary or post-polycythemia vera/essential
thrombocythemia myelofibrosis.